Abstract 420P
Background
KRAS mutations define a molecular subgroup of non-small cell lung cancer (NSCLC). KRAS G12C mutations can be targeted by small molecule inhibitors. Further investigation of cellular and molecular components of KRASm NSCLC is warranted to understand the disease mechanisms and guide precise treatment.
Methods
Tumor specimens of KRASm NSCLC were histologically evaluated, DNA and RNA were extracted. Comprehensive genomic and transcriptomic profiling were detected by Illumina TruSight Oncology 500 kit and TruSeq RNA Exome kit. Correlation analysis included demographic and clinical data as well.
Results
Among 162 cases of KRASm NSCLC, there were 141 males and 21 females, 140 adenocarcinoma and 8 squamous cell carcinoma, 2 sarcoid carcinoma, 1 large cell carcinoma and 1 NOS, 121 smokers and 41 non-smokers. Using next-generation sequencing (NGS), C>T transition signatures were found most often, followed by C>A, T>C, C>G, T>G, and T>A. KRAS mutations included 68 G12Cs, 33 G12Ds, 32 G12Vs, 9 G12As, 6 G13Ds, 6 Q61H/Ls and others. Major co-altered genes included TP53, LRP1B, FAT1, STK11, ARID1B, PTPRD, SPTA1, NOTCH3, NOTCH1, MGA, KEAP1, ZFHX3, etc. The genes co-alterations with KRAS were TP53 (59, 35.1%), followed by STK11 (27, 16.1%), STK11/TP53 (20, 11.9%), CDKN2A/TP53 (7, 4.2%), CDKN2A/STK11 (4, 3.4%) and CDKN2A/STK11/TP53 (3, 1.8%). Using MDACC's report, four groups were established: KL, KP, KC, and K-only. Correlation of genotypes with clinical outcome after adjuvant therapies will be analysed. Compared with adjacent tissues, KRASm cancer tissues had differentially expressed genes (DEGs) enriched in pathways of cytokine receptor interaction, primary immunodeficiency, intestinal immune network for IgA production, and etc. All KRAS tumors can be categorized into low and high inflamed groups by StromalScore, ImmuneScore and ESTIMATEScore methods.
Conclusions
Chinese KRAS mutant lung cancers are highly heterogeneous in terms of both KRAS mutations and co-altered genes and varied in inflammatory status in tumor microenvironment as well. Molecular and immune characteristics in KRASm NSCLC may influence the clinical outcome of adjuvant therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Natural Science Foundation of China.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract